Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Linda Johnson is active.

Publication


Featured researches published by Linda Johnson.


Neuromuscular Disorders | 2013

Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network

Anne M. Connolly; Julaine Florence; Mary Michaeleen Cradock; Elizabeth C. Malkus; Jeanine Schierbecker; Catherine Siener; Charlie Wulf; Pallavi Anand; Paul T. Golumbek; Craig M. Zaidman; J. Philip Miller; Linda Lowes; Lindsay Alfano; Laurence Viollet-Callendret; Kevin M. Flanigan; Craig M. McDonald; E. Goude; Linda Johnson; Alina Nicorici; Peter I. Karachunski; John W. Day; Joline Dalton; Janey M. Farber; Karen K. Buser; Basil T. Darras; Peter B. Kang; Susan Riley; Elizabeth Shriber; Rebecca Parad; Kate Bushby

Therapeutic trials in Duchenne Muscular Dystrophy (DMD) exclude young boys because traditional outcome measures rely on cooperation. The Bayley III Scales of Infant and Toddler Development (Bayley III) have been validated in developing children and those with developmental disorders but have not been studied in DMD. Expanded Hammersmith Functional Motor Scale (HFMSE) and North Star Ambulatory Assessment (NSAA) may also be useful in this young DMD population. Clinical evaluators from the MDA-DMD Clinical Research Network were trained in these assessment tools. Infants and boys with DMD (n = 24; 1.9 ± 0.7 years) were assessed. The mean Bayley III motor composite score was low (82.8 ± 8; p ≤ .0001) (normal = 100 ± 15). Mean gross motor and fine motor function scaled scores were low (both p ≤ .0001). The mean cognitive comprehensive (p=.0002), receptive language (p ≤ .0001), and expressive language (p = .0001) were also low compared to normal children. Age was negatively associated with Bayley III gross motor (r = -0.44; p = .02) but not with fine motor, cognitive, or language scores. HFMSE (n=23) showed a mean score of 31 ± 13. NSAA (n = 18 boys; 2.2 ± 0.4 years) showed a mean score of 12 ± 5. Outcome assessments of young boys with DMD are feasible and in this multicenter study were best demonstrated using the Bayley III.


Muscle & Nerve | 2015

Outcome reliability in non-Ambulatory Boys/Men with duchenne muscular dystrophy

Anne M. Connolly; Elizabeth C. Malkus; Kevin M. Flanigan; J. Philip Miller; Jeanine Schierbecker; Catherine Siener; Paul T. Golumbek; Craig M. Zaidman; Craig M. McDonald; Linda Johnson; Alina Nicorici; Peter I. Karachunski; John W. Day; Jason M. Kelecic; Linda Lowes; Lindsay Alfano; Basil T. Darras; Peter B. Kang; Janet Quigley; Amy Pasternak; Julaine Florence

Introduction: Therapeutic trials in Duchenne muscular dystrophy (DMD) often exclude non‐ambulatory individuals. Here we establish optimal and reliable assessments in a multicenter trial. Methods: Non‐ambulatory boys/men with DMD (N = 91; 16.7 ± 4.5 years of age) were assessed by trained clinical evaluators. Feasibility (percentage completing task) and reliability [intraclass correlation coefficients (ICCs) between morning and afternoon tests] were measured. Results: Forced vital capacity (FVC), assessed in all subjects, showed a mean of 47.8 ± 22% predicted (ICC 0.98). Brooke Upper Extremity Functional Rating (Brooke) and Egen Klassifikation (EK) scales in 100% of subjects showed ICCs ranging from 0.93 to 0.99. Manual muscle testing, range of motion, 9‐hole peg test, and Jebsen‐Taylor Hand Function Test (JHFT) demonstrated varied feasibility (99% to 70%), with ICCs ranging from 0.99 to 0.64. We found beneficial effects of different forms of corticosteroids for the Brooke scale, percent predicted FVC, and hand and finger strength. Conclusions: Reliable assessment of non‐ambulatory boys/men with DMD is possible. Clinical trials will have to consider corticosteroid use. Muscle Nerve 51: 522–532, 2015


Manual Therapy | 2015

Validity and reliability of smartphone magnetometer-based goniometer evaluation of shoulder abduction – A pilot study

Linda Johnson; Sean Sumner; Tina Duong; Posu Yan; Ruzena Bajcsy; R. Ted Abresch; Evan de Bie; Jay J. Han

BACKGROUND Goniometers are commonly used by physical therapists to measure range-of-motion (ROM) in the musculoskeletal system. These measurements are used to assist in diagnosis and to help monitor treatment efficacy. With newly emerging technologies, smartphone-based applications are being explored for measuring joint angles and movement. OBJECTIVE This pilot study investigates the intra- and inter-rater reliability as well as concurrent validity of a newly-developed smartphone magnetometer-based goniometer (MG) application for measuring passive shoulder abduction in both sitting and supine positions, and compare against the traditional universal goniometer (UG). DESIGN This is a comparative study with repeated measurement design. METHODS Three physical therapists utilized both the smartphone MG and a traditional UG to measure various angles of passive shoulder abduction in a healthy subject, whose shoulder was positioned in eight different positions with pre-determined degree of abduction while seated or supine. Each therapist was blinded to the measured angles. Concordance correlation coefficients (CCCs), Bland-Altman plotting methods, and Analysis of Variance (ANOVA) were used for statistical analyses. RESULTS Both traditional UG and smartphone MG were reliable in repeated measures of standardized joint angle positions (average CCC > 0.997) with similar variability in both measurement tools (standard deviation (SD) ± 4°). Agreement between the UG and MG measurements was greater than 0.99 in all positions. CONCLUSION Our results show that the smartphone MG has equivalent reliability compared to the traditional UG when measuring passive shoulder abduction ROM. With concordant measures and comparable reliability to the UG, the newly developed MG application shows potential as a useful tool to assess joint angles.


Muscle & Nerve | 2016

Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA–DMD network follow-up

Anne M. Connolly; Julaine Florence; Craig M. Zaidman; Paul T. Golumbek; Kevin M. Flanigan; Peter I. Karachunski; John W. Day; Craig M. McDonald; Basil T. Darras; Peter B. Kang; Catherine Siener; Rebecca K. Gadeken; Pallavi Anand; Jeanine Schierbecker; Elizabeth C. Malkus; Linda Lowes; Lindsay Alfano; Linda Johnson; Alina Nicorici; Jason M. Kelecic; Janet Quigley; Amy Pasternak; J. Philip Miller

Introduction: Outcomes sensitive to change over time in non‐ambulatory boys/men with Duchenne muscular dystrophy (DMD) are not well‐established. Methods: Subjects (n = 91; 16.8 ± 4.5 years old) were assessed at baseline and 6‐month intervals for 2 years. We analyzed all subjects using an intent‐to‐treat model and a subset of stronger subjects with Brooke Scale score ≤4, using repeated measures. Results: Eight patients (12–33 years old) died during the study. Sixty‐six completed 12‐month follow‐up, and 51 completed 24‐month follow‐up. Those taking corticosteroids performed better at baseline, but rates of decline were similar. Forced vital capacity percent predicted (FVC% predicted) declined significantly only after 2 years. However, Brooke and Egen Klassifikation (EK) Scale scores, elbow flexion, and grip strength declined significantly over both 1 and 2 years. Conclusion: Brooke and EK Scale scores, elbow flexion, and grip strength were outcomes most responsive to change. FVC% predicted was responsive to change over 2 years. Corticosteroids benefited non‐ambulatory DMD subjects but did not affect decline rates of measures tested here. Muscle Nerve 54: 681–689, 2016


Physical Medicine and Rehabilitation Clinics of North America | 2012

Physical therapy evaluation and management in neuromuscular diseases.

Linda Johnson; Julaine Florence; R. Ted Abresch

Neuromuscular disorders (NMDs) are a group of myopathic or neuropathic diseases that directly or indirectly affect the functioning of muscle. Physical therapists (PTs) have extensive specialized training in musculoskeletal evaluation and assessment that gives them the tools to meet the significant needs of this population. This article reviews the role of PTs in treating the NMD population with a discussion of available evaluation techniques and interventions and with an effort to differentiate between treatments known to apply to this population and conventional practice of PTs. The status of currently available outcome measures used for research and their applicability to clinics are presented.


Studies in health technology and informatics | 2013

mHealth application for upper extremity range of motion and reachable workspace.

Posu Yan; Gregorij Kurillo; Ruzena Bajcsy; Richard T. Abresch; Alina Nicorici; Linda Johnson; Jay J. Han

We present mobile health (mHealth) applications utilizing embedded phone sensors as an angle-measuring device for upper-limb range of motion (ROM) and estimation of reachable workspace to assist in evaluation of upper limb functional capacity. Our results show that the phone can record accurate measurements, as well as provide additional functionalities for clinicians.


Muscle & Nerve | 2016

Clinical trial readiness in non‐ambulatory boys and men with DMD: MDA‐DMD network follow‐up

Anne M. Connolly; Julaine Florence; Craig M. Zaidman; Paul T. Golumbek; Kevin M. Flanigan; Peter I. Karachunski; John W. Day; Craig M. McDonald; Basil T. Darras; Peter B. Kang; Catherine Siener; Rebecca K. Gadeken; Pallavi Anand; Jeanine Schierbecker; Elizabeth C. Malkus; Linda Lowes; Lindsay Alfano; Linda Johnson; Alina Nicorici; Jason M. Kelecic; Janet Quigley; Amy Pasternak; J. Philip Miller

Introduction: Outcomes sensitive to change over time in non‐ambulatory boys/men with Duchenne muscular dystrophy (DMD) are not well‐established. Methods: Subjects (n = 91; 16.8 ± 4.5 years old) were assessed at baseline and 6‐month intervals for 2 years. We analyzed all subjects using an intent‐to‐treat model and a subset of stronger subjects with Brooke Scale score ≤4, using repeated measures. Results: Eight patients (12–33 years old) died during the study. Sixty‐six completed 12‐month follow‐up, and 51 completed 24‐month follow‐up. Those taking corticosteroids performed better at baseline, but rates of decline were similar. Forced vital capacity percent predicted (FVC% predicted) declined significantly only after 2 years. However, Brooke and Egen Klassifikation (EK) Scale scores, elbow flexion, and grip strength declined significantly over both 1 and 2 years. Conclusion: Brooke and EK Scale scores, elbow flexion, and grip strength were outcomes most responsive to change. FVC% predicted was responsive to change over 2 years. Corticosteroids benefited non‐ambulatory DMD subjects but did not affect decline rates of measures tested here. Muscle Nerve 54: 681–689, 2016


Neuromuscular Disorders | 2013

P.2.4 Upper extremity reachable workspace evaluation in DMD using Kinect

G. Kurillo; Jay Han; Alina Nicorici; Linda Johnson; Richard T. Abresch; Erik Henricson; Craig M. McDonald; R. Bajcsy


Neurology | 2012

Motor and Cognitive Assessment of Infants and Young Boys with Duchenne Muscular Dystrophy; Results from the Muscular Dystrophy Association DMD Clinical Research Center Network (P04.084)

Anne M. Connolly; Julaine Florence; Mary Michaeleen Cradock; Elizabeth C. Malkus; Jeanine Schierbecker; Catherine Siener; Charlie Wulf; Pallavi Anand; Linda Lowes; Lindsay Alfano; Laurence Viollet-Callendret; Kevin M. Flanigan; Craig M. McDonald; E. Goude; Linda Johnson; Alina Nicorici; Peter I. Karachunski; John W. Day; Joline Dalton; Janey M. Farber; Karen K. Buser; Basil T. Darras; Susan Riley; Elizabeth Schriber; Rebecca Parad; Kate Bushby; Michelle Eagle


Neuromuscular Disorders | 2014

G.P.167

Anne M. Connolly; Elizabeth C. Malkus; Jeanine Schierbecker; Catherine Siener; Pallavi Anand; Kevin M. Flanigan; Paul T. Golumbek; Craig M. Zaidman; Craig M. McDonald; Erik Henricson; Linda Johnson; Alina Nicorici; Peter I. Karachunski; John W. Day; Jason M. Kelecic; Linda Lowes; Lindsay Alfano; Basil T. Darras; Peter B. Kang; J. Florence

Collaboration


Dive into the Linda Johnson's collaboration.

Top Co-Authors

Avatar

Alina Nicorici

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anne M. Connolly

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Basil T. Darras

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Catherine Siener

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Elizabeth C. Malkus

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Jeanine Schierbecker

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kevin M. Flanigan

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Linda Lowes

Nationwide Children's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge